VIVUS, Inc. was trending higher on Tuesday, after the Food and Drug Administration granted the firm approval to sell its weight-loss drug, Qsymia, in retail pharmacies.
http://www.schaeffersresearch.com/marketcenters/optionscenter/content/vivus+inc+vvus+sees+a+rare+jump+in+near-term+call+volume/default.aspx?ID=115667&c=obsfeed
http://www.schaeffersresearch.com/marketcenters/optionscenter/content/vivus+inc+vvus+sees+a+rare+jump+in+near-term+call+volume/default.aspx?ID=115667&c=obsfeed
No comments:
Post a Comment